Free Trial

Brown Capital Management LLC Sells 60,621 Shares of Vericel Co. (NASDAQ:VCEL)

Vericel logo with Medical background

Brown Capital Management LLC cut its holdings in Vericel Co. (NASDAQ:VCEL - Free Report) by 0.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,818,933 shares of the biotechnology company's stock after selling 60,621 shares during the period. Vericel makes up approximately 3.6% of Brown Capital Management LLC's investment portfolio, making the stock its 12th largest position. Brown Capital Management LLC owned about 14.29% of Vericel worth $242,822,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. PNC Financial Services Group Inc. increased its holdings in shares of Vericel by 8.1% during the third quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company's stock worth $154,000 after purchasing an additional 344 shares during the period. Gotham Asset Management LLC increased its position in Vericel by 3.6% in the 3rd quarter. Gotham Asset Management LLC now owns 15,311 shares of the biotechnology company's stock valued at $513,000 after acquiring an additional 538 shares during the period. Aigen Investment Management LP raised its stake in shares of Vericel by 8.7% during the fourth quarter. Aigen Investment Management LP now owns 8,326 shares of the biotechnology company's stock valued at $296,000 after acquiring an additional 667 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Vericel by 0.5% during the third quarter. Rhumbline Advisers now owns 145,224 shares of the biotechnology company's stock worth $4,868,000 after purchasing an additional 705 shares during the period. Finally, Trexquant Investment LP grew its stake in shares of Vericel by 1.8% in the fourth quarter. Trexquant Investment LP now owns 43,882 shares of the biotechnology company's stock worth $1,563,000 after purchasing an additional 763 shares during the last quarter.


Insider Activity at Vericel

In other Vericel news, Director Robert L. Md Zerbe sold 3,278 shares of the stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total value of $169,046.46. Following the transaction, the director now owns 23,395 shares in the company, valued at $1,206,480.15. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Vericel news, Director Robert L. Md Zerbe sold 3,278 shares of the firm's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $51.57, for a total value of $169,046.46. Following the transaction, the director now directly owns 23,395 shares of the company's stock, valued at $1,206,480.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Dominick Colangelo sold 17,500 shares of the business's stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $44.59, for a total transaction of $780,325.00. Following the sale, the chief executive officer now directly owns 195,307 shares of the company's stock, valued at $8,708,739.13. The disclosure for this sale can be found here. 7.20% of the stock is currently owned by corporate insiders.

Vericel Stock Down 0.4 %

VCEL traded down $0.17 during trading on Thursday, hitting $43.35. The company's stock had a trading volume of 352,061 shares, compared to its average volume of 487,110. The firm has a market capitalization of $2.11 billion, a P/E ratio of -4,347.65 and a beta of 1.74. Vericel Co. has a twelve month low of $30.18 and a twelve month high of $53.05. The stock's fifty day moving average price is $47.48 and its 200-day moving average price is $43.76.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The business had revenue of $51.28 million for the quarter, compared to analyst estimates of $49.07 million. During the same period in the prior year, the firm earned ($0.16) earnings per share. Vericel's revenue was up 25.0% on a year-over-year basis. Equities research analysts expect that Vericel Co. will post 0.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on VCEL. StockNews.com downgraded Vericel from a "hold" rating to a "sell" rating in a report on Thursday, June 6th. Truist Financial reaffirmed a "buy" rating and issued a $54.00 price objective on shares of Vericel in a research note on Tuesday, March 26th. Finally, HC Wainwright increased their target price on shares of Vericel from $53.00 to $55.00 and gave the company a "buy" rating in a research report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, Vericel presently has an average rating of "Moderate Buy" and a consensus target price of $46.80.

Check Out Our Latest Stock Report on Vericel

About Vericel

(Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Featured Stories

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Should you invest $1,000 in Vericel right now?

Before you consider Vericel, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.

While Vericel currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines